Market Overview

KITE PHARMA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout


Rigrodsky & Long, P.A.:

  • Do you own shares of Kite Pharma, Inc. (NASDAQ GS: KITE)?
  • Did you purchase any of your shares prior to August 28, 2017?
  • Do you think the proposed buyout is fair?
  • Do you want to discuss your rights?

& Long, P.A.
announces that it is investigating potential legal
claims against the board of directors of Kite Pharma, Inc. ("Kite
Pharma" or the "Company") (NASDAQ GS: KITE)
regarding possible breaches of fiduciary duties and other violations of
law related to the Company's entry into an agreement to be acquired by
Gilead Sciences, Inc. ("Gilead") (NASDAQ GS: GILD)
in a transaction valued at approximately $11.9 billion. Under the terms
of the agreement, shareholders of Kite Pharma will receive $180.00 in
cash for each share of Kite Pharma common stock.

If you own common stock of Kite Pharma and purchased any shares before
August 28, 2017, if you would like to learn more about this
investigation, or if you have any questions concerning this announcement
or your rights or interests, please contact Seth D. Rigrodsky or Gina M.
Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120,
Wilmington, DE 19803, by telephone at (888) 969-4242, or by e-mail at

& Long, P.A.
, with offices in Wilmington, Delaware and Garden
City, New York, regularly prosecutes securities
fraud, shareholder corporate, and shareholder derivative litigation

on behalf of shareholders in state and federal courts throughout the
United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

View Comments and Join the Discussion!